Dialectic Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Later Stage VC
- Investors
-
3
Dialectic Therapeutics General Information
Description
Operator of a biotechnology company intended to create new technologies to treat cancer. The company's drugs specialize in inducing cancer cells to degrade B-cell lymphoma, stimulating the cells to commit suicide or become susceptible to chemotherapy, enabling patients to have increased disease-free survival.
Contact Information
Website
www.dtsciences.comCorporate Office
- 12200 North Stemmons Freeway
- Suite 100
- Dallas, TX 75234
- United States
Corporate Office
- 12200 North Stemmons Freeway
- Suite 100
- Dallas, TX 75234
- United States
Dialectic Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 01-Mar-2023 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 20-Aug-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Seed Round | 11-Feb-2021 | Completed | Clinical Trials - Phase 1 | |||
| 4. Angel (individual) | 06-Oct-2020 | Completed | Startup | |||
| 3. Grant | 26-Feb-2020 | Completed | Startup | |||
| 2. Seed Round | 13-Nov-2018 | $2M | $2M | Completed | Startup | |
| 1. Spin-Off | 01-Jan-2018 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Dialectic Therapeutics Patents
Dialectic Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026050093-A1 | Combination therapies for the treatment of advanced malignancies including solid tumors | Pending | 27-Aug-2024 | ||
| AU-2021377235-A1 | Small molecule formulation | Pending | 10-Nov-2020 | ||
| AU-2021377235-A9 | Small molecule formulation | Pending | 10-Nov-2020 | ||
| CA-3196536-A1 | Small molecule formulation | Pending | 10-Nov-2020 | ||
| EP-4243775-A1 | Small molecule formulation | Pending | 10-Nov-2020 | A61K9/107 |
Dialectic Therapeutics Signals
Dialectic Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Altamont Pharmaceutical Holdings | Holding Company | Minority | ||
| Cancer Prevention and Research Institute of Texas | Government | |||
| University of Florida | University |
Dialectic Therapeutics FAQs
-
When was Dialectic Therapeutics founded?
Dialectic Therapeutics was founded in 2018.
-
Where is Dialectic Therapeutics headquartered?
Dialectic Therapeutics is headquartered in Dallas, TX.
-
What is the size of Dialectic Therapeutics?
Dialectic Therapeutics has 5 total employees.
-
What industry is Dialectic Therapeutics in?
Dialectic Therapeutics’s primary industry is Drug Discovery.
-
Is Dialectic Therapeutics a private or public company?
Dialectic Therapeutics is a Private company.
-
What is Dialectic Therapeutics’s current revenue?
The current revenue for Dialectic Therapeutics is .
-
How much funding has Dialectic Therapeutics raised over time?
Dialectic Therapeutics has raised $8.85M.
-
Who are Dialectic Therapeutics’s investors?
Altamont Pharmaceutical Holdings, Cancer Prevention and Research Institute of Texas, and University of Florida have invested in Dialectic Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process